Harada K, Okamoto H, Fujioka Y, Uozumi T, Kiya K, Kitaoka T, Goishi A, Sasaki U, Shima T, Inagawa T
Gan To Kagaku Ryoho. 1985 Jul;12(7):1423-31.
A total of 71 cases with primary brain tumors (44 cases) and metastatic brain tumors (30 cases) were entered into our clinical studies with MCNU and radiation therapy or MCNU alone. With regard to tumor reduction on CT scan, the response rates obtained for MCNU and radiation were 21.7% for malignant gliomas and 50.0% for metastatic brain tumors. With regard to improvement of neurological signs, the response rates obtained for MCNU and radiation were 62.9% for malignant gliomas and 71.4% for metastatic brain tumors. The response rates for MCNU were 5.8% for malignant gliomas and 46.1% for metastatic brain tumors. In the improvement of performance status, the response rates for MCNU and radiation were 51.8% for malignant gliomas and 64.2% for metastatic brain tumors. The response rates for MCNU were 46.1% for malignant gliomas and 30.7% for metastatic brain tumors. A minimal degree of hematological toxicity occurred but this gradually disappeared. These results suggested that MCNU has relatively effective antitumor activity against metastatic brain tumors and an enhanced effect with radiation against malignant gliomas.
共有71例原发性脑肿瘤（44例）和转移性脑肿瘤（30例）患者进入我们关于甲环亚硝脲（MCNU）与放射治疗联合或单纯使用MCNU的临床研究。关于CT扫描上肿瘤缩小情况，MCNU与放疗联合应用时，恶性胶质瘤的缓解率为21.7%，转移性脑肿瘤的缓解率为50.0%。关于神经体征改善情况，MCNU与放疗联合应用时，恶性胶质瘤的缓解率为62.9%，转移性脑肿瘤的缓解率为71.4%。MCNU单独应用时，恶性胶质瘤的缓解率为5.8%，转移性脑肿瘤的缓解率为46.1%。在改善身体状况方面，MCNU与放疗联合应用时，恶性胶质瘤的缓解率为51.8%，转移性脑肿瘤的缓解率为64.2%。MCNU单独应用时，恶性胶质瘤的缓解率为46.1%，转移性脑肿瘤的缓解率为30.7%。出现了最低程度的血液学毒性，但这种毒性逐渐消失。这些结果表明，MCNU对转移性脑肿瘤具有相对有效的抗肿瘤活性，与放疗联合对恶性胶质瘤有增强疗效。
